Drugs / Perflutren Protein-Type A Microspheres
Perflutren Protein-Type A Microspheres
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT05328167 | Dec 2021 → Jul 2025 | intrahepatic cholangiocarcinoma | Thomas Jefferson University | Completed | No outcome recorded |
| Phase 2 | NCT03199274 | Jul 2017 → Feb 2024 | hepatocellular carcinoma | Thomas Jefferson University | Completed | Met primary |
| Phase 41 trial | ||||||
| Phase 4 | NCT00730964 | May 2008 → Oct 2009 | — | GE Healthcare | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00239525 | May 2006 → Apr 2007 | intracranial hypertension, stroke disorder | Duke University | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 0 | NCT02671552 Background | Jan 2013 → Dec 2014 | renal cell carcinoma | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Perflutren Protein-Type A Microspheres | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00239525 ↗ |
| Modality | Diagnostic / imaging agent | “ultrasound contrast agents” NCT00239525 ↗ |
| Route | Intravenous | “by intravenous bolus injection” NCT00239525 ↗ |